4B Technologies was selected into the list of "2023 China Biomedical Industry Front-runners 100”

Recently, 4B Biotechnologies was selected for the "2023 China Biomedical Industry Front-runners 100" list.

4B Technologies was selected into the final list of KPMG China Future Sector 50 Ranking Series—Biotech

4B Technologies was selected into the final list of KPMG China Future Sector 50 Ranking Series—Biotech

4B Technologies’ category 1 innovative monoclonal antibody drug approved for clinical trial

On March 20, 2023, FB1001 has been granted clinical trial approval by CDE